MA41136A - Composés pour le traitement d'un cancer - Google Patents

Composés pour le traitement d'un cancer

Info

Publication number
MA41136A
MA41136A MA041136A MA41136A MA41136A MA 41136 A MA41136 A MA 41136A MA 041136 A MA041136 A MA 041136A MA 41136 A MA41136 A MA 41136A MA 41136 A MA41136 A MA 41136A
Authority
MA
Morocco
Prior art keywords
cancer
compounds
treatment
Prior art date
Application number
MA041136A
Other languages
English (en)
Inventor
Ursula Krenz
Hans-Georg Lerchen
Philip Lienau
Ulrich Lücking
Volker Schulze
Gerhard Siemeister
Antje Margret Wengner
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA41136A publication Critical patent/MA41136A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA041136A 2014-12-09 2015-12-06 Composés pour le traitement d'un cancer MA41136A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14196859 2014-12-09

Publications (1)

Publication Number Publication Date
MA41136A true MA41136A (fr) 2017-10-17

Family

ID=52011093

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041136A MA41136A (fr) 2014-12-09 2015-12-06 Composés pour le traitement d'un cancer

Country Status (27)

Country Link
US (1) US20170342064A1 (fr)
EP (1) EP3230285A1 (fr)
JP (1) JP2017537116A (fr)
KR (1) KR20170088872A (fr)
CN (1) CN107001376A (fr)
AR (1) AR102947A1 (fr)
AU (1) AU2015359593A1 (fr)
BR (1) BR112017012317A2 (fr)
CA (1) CA2969902A1 (fr)
CO (1) CO2017005741A2 (fr)
CR (1) CR20170243A (fr)
CU (1) CU20170078A7 (fr)
DO (1) DOP2017000136A (fr)
EA (1) EA201791264A1 (fr)
EC (1) ECSP17036251A (fr)
IL (1) IL252237A0 (fr)
MA (1) MA41136A (fr)
MX (1) MX2017007655A (fr)
NI (1) NI201700072A (fr)
PE (1) PE20170927A1 (fr)
PH (1) PH12017501063A1 (fr)
SG (1) SG11201704684PA (fr)
TN (1) TN2017000241A1 (fr)
TW (1) TW201625565A (fr)
UY (1) UY36421A (fr)
WO (1) WO2016091825A1 (fr)
ZA (1) ZA201704589B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022159702A1 (fr) * 2021-01-22 2022-07-28 Biogen Ma Inc. Additifs de déstabilisation de microtubules pour augmenter les titres de vecteurs viraux recombinés

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007223342A1 (en) * 2006-03-07 2007-09-13 Bristol-Myers Squibb Company Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
CA2914745A1 (fr) * 2013-06-11 2014-12-18 Bayer Pharma Aktiengesellschaft Derives de type promedicament de triazolopyridines substituees

Also Published As

Publication number Publication date
CU20170078A7 (es) 2017-10-05
IL252237A0 (en) 2017-07-31
AU2015359593A1 (en) 2017-06-08
AR102947A1 (es) 2017-04-05
TW201625565A (zh) 2016-07-16
KR20170088872A (ko) 2017-08-02
ECSP17036251A (es) 2017-06-30
SG11201704684PA (en) 2017-07-28
TN2017000241A1 (en) 2018-10-19
EP3230285A1 (fr) 2017-10-18
JP2017537116A (ja) 2017-12-14
PE20170927A1 (es) 2017-07-13
CR20170243A (es) 2017-07-26
CA2969902A1 (fr) 2016-06-16
BR112017012317A2 (pt) 2018-04-24
WO2016091825A1 (fr) 2016-06-16
UY36421A (es) 2016-06-30
CN107001376A (zh) 2017-08-01
PH12017501063A1 (en) 2017-12-11
US20170342064A1 (en) 2017-11-30
MX2017007655A (es) 2017-10-11
NI201700072A (es) 2017-07-17
EA201791264A1 (ru) 2017-12-29
CO2017005741A2 (es) 2017-08-31
DOP2017000136A (es) 2017-08-31
ZA201704589B (en) 2019-02-27

Similar Documents

Publication Publication Date Title
FR25C1001I2 (fr) Compositions d'anticorps pour le traitement de tumeurs
MA49144A (fr) Polythérapies pour le traitement du cancer
MA45192A (fr) Traitement d'association
EP3397963A4 (fr) Inhibition de mapk p38 pour le traitement du cancer
EP3452060A4 (fr) Polythérapie pour le traitement du cancer
MA41449A (fr) Polythérapies pour le traitement de cancers
EP3013345A4 (fr) Composés pour le traitement d'une amyotrophie spinale
EP3362066A4 (fr) Polythérapie pour le traitement de tumeurs malignes
MA50409A (fr) Polythérapies pour le traitement du cancer
EP3400010A4 (fr) Combinaisons anti-her2 pour le traitement des tumeurs
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
MA48637A (fr) Polythérapies pour le traitement du cancer
EP3362065A4 (fr) Polythérapie pour le traitement de malignités
EP3400011A4 (fr) Combinaisons anti-cd20 pour le traitement des tumeurs
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
EP3380200A4 (fr) Compositions pour le traitement des cheveux
EP3541417A4 (fr) Immunothérapies d'association pour le traitement du cancer
EP3630196A4 (fr) Polythérapies pour le traitement de cancers
EP3335041A4 (fr) Biomarqueurs pour le traitement de la pelade
EP3490561A4 (fr) Combinaisons pour le traitement du cancer
EP3380063A4 (fr) Compositions pour le traitement des cheveux
MA41123A (fr) Polythérapie pour le traitement du cancer
EP3334432A4 (fr) Cerdulatinib pour le traitement du myélome
EP3416645A4 (fr) Composés pour le traitement du paludisme